The Top 5 Biosimilar Articles for the Week of October 3

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 3, 2022.

Number 5: Sarfaraz K. Niazi, PhD, explains the significance of the European Medicines Agency (EMA) declaring that biosimilars are interchangeable with their reference products and calls for the United States to do the same in the first installment of his new monthly column.

Number 4: The final part of a 4-part series assesses what payers should know about the US introduction of adalimumab biosimilars coming in 2023 as well as policy considerations they can implement to reap the benefits of biosimilar savings.

Number 3: Health Canada approved Lupin Limited’s Rymti, the third etanercept biosimilar to be granted regulatory approval in the country. Meanwhile, Prestige Biopharma announced that it withdrew its European application for its trastuzumab biosimilar.

Number 2: The FDA approved Celltrion Healthcare’s Vegzelma (bevacizumab-adcd; CT-P16), a biosimilar referencing Genentech’s Avastin. The approval marks the fourth bevacizumab biosmilar to be approved in the United States.

Number 1: One of the first provisions of the Inflation Reduction Act—a 5-year temporary increase in the add-on payment for qualifying biosimilars to encourage their utilization—took affect October 3.

To read all of these articles and more, visit centerforbiosimilars.com.